Skip to main content
OpenTrials
Completed

NCT Number: NCT00756145

The Use of Low Molecular Weight Heparin in Hemodiafiltration

Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Kidney Disease Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Hospital Ghent

Ghent, 9000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • chronic kidney disease stade V treated with hemodiafiltration
  • age >18 year
  • Hematocrit > 30%

Exclusion criteria

  • treatment with vitamin K antagonists
  • treatment with other anti-coagulants or heparin besides the heparin used during dialysis
  • active bleeding, infection or malignancy
  • heparin associated allergy
  • hepatic failure
  • trombocytopenia < 120.000/µl

Treatment and study plan

At start of the session, at the inlet line

Procedure

Injection of LMWH at the inlet line, at the start of the hemodiafiltration session

5 minutes after the start of the session, at the inlet line

Procedure

Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session

At the start of the session, at the outlet line

Procedure

Injection of LMWH at the outlet line, at the start of the hemodiafiltration session

Primary outcomes

  1. Anti-Xa activity at the end of the session

    Time frame: 240 min after start

Secondary outcomes

  1. Anti-Xa activity during the session

    Time frame: at start, 30 min, 120 min and 180 min

  2. ETP during the session

    Time frame: at start, 30 min, 120 min, 180 min and 240 min

  3. Reduction ratio of urea

    Time frame: after 10min, 180min and 240min

  4. Reduction ratio of beta2microglobulin

    Time frame: after 10min, 180min and 240min

  5. Visual inspection of membrane and circuit

    Time frame: After the hemodiafiltration session

  6. pressure measurements along the circuit

    Time frame: during the session

    inlet blood line, prefilter, transmembrane, outlet blood line

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Registry information

Important dates

Study start
2008
Primary completion
2015
Study completion
2015
First posted
Sep 19, 2008
Registry last updated
May 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.